Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVO NYSE:OGEN OTCMKTS:SKVI NASDAQ:TCRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.47-2.0%$2.36$1.43▼$381.10$4.84M5.77908,918 shs235,848 shsOGENOragenics$1.19+3.8%$1.25$1.01▼$18.90$4.85M0.82308,161 shs128,298 shsSKVISkinvisible$0.08-64.7%$0.20$0.08▼$0.85$438K0.865,390 shs760 shsTCRTAlaunos Therapeutics$2.32-2.7%$2.85$1.31▼$6.20$5.08M-0.82232,172 shs33,184 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics0.00%-7.98%-27.18%-65.83%-99.98%OGENOragenics+1.32%+8.49%-1.71%-73.62%-92.33%SKVISkinvisible0.00%+9.48%+21.51%+30.40%-71.96%TCRTAlaunos Therapeutics+8.68%+10.19%-2.46%-21.45%+1.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.47-2.0%$2.36$1.43▼$381.10$4.84M5.77908,918 shs235,848 shsOGENOragenics$1.19+3.8%$1.25$1.01▼$18.90$4.85M0.82308,161 shs128,298 shsSKVISkinvisible$0.08-64.7%$0.20$0.08▼$0.85$438K0.865,390 shs760 shsTCRTAlaunos Therapeutics$2.32-2.7%$2.85$1.31▼$6.20$5.08M-0.82232,172 shs33,184 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics0.00%-7.98%-27.18%-65.83%-99.98%OGENOragenics+1.32%+8.49%-1.71%-73.62%-92.33%SKVISkinvisible0.00%+9.48%+21.51%+30.40%-71.96%TCRTAlaunos Therapeutics+8.68%+10.19%-2.46%-21.45%+1.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$219,040.0014,900,580.27% UpsideOGENOragenics 0.00N/AN/AN/ASKVISkinvisible 0.00N/AN/AN/ATCRTAlaunos Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M1.56N/AN/A$65.21 per share0.02OGENOragenicsN/AN/AN/AN/A$0.61 per shareN/ASKVISkinvisible$20K21.90N/AN/A($1.86) per share-0.04TCRTAlaunos Therapeutics$10K511.62N/AN/A$1.29 per share1.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-675.52%-175.68%11/6/2025 (Estimated)OGENOragenics-$20.66M-$21.42N/A∞N/AN/A-2,087.95%-486.56%N/ASKVISkinvisible-$570K-$0.08N/A∞N/A-2,635.00%N/A-351.46%N/ATCRTAlaunos Therapeutics-$4.68M-$2.46N/A∞N/AN/A-168.02%-121.37%11/12/2025 (Estimated)Latest SKVI, APVO, TCRT, and OGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TCRTAlaunos Therapeutics-$5.3340-$0.63+$4.7040-$0.63N/AN/A8/13/2025Q2 2025SKVISkinvisibleN/A-$0.05N/A-$0.05N/AN/A8/11/2025Q2 2025APVOAptevo Therapeutics-$83.20-$8.40+$74.80-$8.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/ASKVISkinvisibleN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A2.272.27OGENOragenicsN/A1.931.93SKVISkinvisibleN/A0.010.01TCRTAlaunos TherapeuticsN/A3.483.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%OGENOragenics18.71%SKVISkinvisibleN/ATCRTAlaunos Therapeutics27.72%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.01%OGENOragenics10.10%SKVISkinvisible53.00%TCRTAlaunos Therapeutics16.14%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics503.29 million3.29 millionNot OptionableOGENOragenics54.13 million10.98 millionN/ASKVISkinvisible25.40 million2.54 millionNot OptionableTCRTAlaunos Therapeutics402.21 million1.85 millionNo DataSKVI, APVO, TCRT, and OGEN HeadlinesRecent News About These CompaniesAlaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest UpdateSeptember 12 at 4:13 AM | americanbankingnews.comAlaunos Therapeutics files $50M mixed securities shelfAugust 21, 2025 | msn.comAlaunos Therapeutics files $50M mixed securities shelfAugust 21, 2025 | msn.comAlaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market ImplicationsAugust 12, 2025 | msn.comAlaunos Therapeutics Appoints Holger Weis as New CEOJuly 25, 2025 | theglobeandmail.comAlaunos Therapeutics Taps Board Member Weis as Next CEOJuly 2, 2025 | marketwatch.comAlaunos Therapeutics, Inc. (TCRT) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comAlaunos Therapeutics Raises $850,000 in Private OfferingJune 26, 2025 | tipranks.comAlaunos Therapeutics Announces $2.0 Million Registered Direct Offering - MorningstarJune 24, 2025 | morningstar.comMAlaunos Therapeutics Announces $2.0 Million Registered Direct OfferingJune 23, 2025 | globenewswire.comAlaunos Therapeutics Amends Warrant Agreement with Mast HillJune 10, 2025 | tipranks.comPMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)May 14, 2025 | globenewswire.comAlaunos Therapeutics announces board member resignationApril 20, 2025 | investing.comThese 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?April 7, 2025 | msn.comPrecigen Terminates License Agreement With Alaunos TherapeuticsOctober 11, 2024 | marketwatch.comAfter axing its sole clinical prospect last year, Alaunos cuts ties with PrecigenOctober 11, 2024 | fiercebiotech.comFAlaunos Therapeutics Ends Licensing Deal, Reassesses StrategyOctober 11, 2024 | finance.yahoo.comAlaunos Therapeutics (NASDAQ:TCRT) Stock, Short Interest ReportSeptember 26, 2024 | benzinga.comAlaunos Therapeutics (NASDAQ:TCRT) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comStella Pharma Corporation (4888.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSKVI, APVO, TCRT, and OGEN Company DescriptionsAptevo Therapeutics NASDAQ:APVO$1.47 -0.03 (-2.00%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Oragenics NYSE:OGEN$1.19 +0.04 (+3.83%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Skinvisible OTCMKTS:SKVI$0.08 -0.15 (-64.72%) As of 03:13 PM EasternSkinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.Alaunos Therapeutics NASDAQ:TCRT$2.32 -0.07 (-2.73%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
